INTRODUCTION AND OBJECTIVES: Abiraterone and enzalutamide are both oral chemotherapeutic agents used in metastatic prostate cancer that have been aggressively marketed to physicians since FDA approval in 2011 and 2012, respectively. We sought to investigate if there is an association between pharmaceutical industry payments to physicians and prescriptions for abiraterone and enzalutamide.
METHODS: Using the Open Payments Database from 2014, we determined the number and total dollar amount of payments from industry to each urologist or oncologist who prescribed abiraterone and enzalutamide. These data were merged with the 2013 Medicare Part D Provider and Utilization Data to identify the total claim count ascribed to each physician as well as the total drug cost per prescribing physician. Drug costs (primary outcome) and claim counts (secondary outcome) were compared between prescribers who did and did not receive industry payment using Wilcoxon rank-sum tests. A Spearman Rank correlation was used to assess the relationship between industry payments and total drug costs/total claim counts for each drug.
RESULTS: For abiraterone, we identified 4918 Open Payment recipients and 1197 prescribers, of whom 615 were both recipients and prescribers. The median payment amount to prescribers was $72 (IQR $26-$114). For enzalutamide, we identified 7820 Open Payment recipients and 412 prescribers, of whom 289 were both recipients and prescribers. The median payment amount to prescribers was 59$ (IQR $25-$148). There was no statistical association between industry payment amount and total drug costs among abiraterone prescribers (r ¼ 0.07, p ¼ 0.11) and there was a small association among enzalutamide prescribers (r ¼ 0.33, p < 0.001) ( Figure) .
CONCLUSIONS: Industry payments to prescribers of abiraterone and enzalutamide were common but of low amount. There was a small association between total drug costs and industry payments for prescribers of enzalutamide, but not abiraterone. Continued public reporting of industry payments to physicians will allow for further investigation of this relationship. METHODS: The publicly available www.clinicaltrials.gov website was individually queried for new trials first received between 2006 and 2015 for the following search terms: "prostate cancer," "kidney cancer" and "bladder cancer." Each category was then stratified by funder type including: NIH, Industry, Other Federal Agency and all others (individuals, universities, organizations.) Trends in funding sources across the decade were examined. RESULTS: Newly registered clinical trials from 2006 to 2015 included 2,487 prostate, 901 kidney and 517 bladder trials, with an upward trend in overall, prostate and bladder trials across the decade. Figure 1 reflects the distribution among cancer type. For all three malignancies, the absolute number of NIH-funded trials decreased while industry funded trials increased when comparing 2006 to 2015. Prostate cancer: NIH: 52 / 36, Industry: 67 / 83 (p¼0.043) Kidney cancer: NIH: 37 / 15, Industry: 28 / 38 (p¼0.002) Bladder cancer: NIH 15 / 10, Industry 12 / 39 (p¼0.002). Similarly, the percentage of NIH funded trials showed a progressive decrease across the decade for all three malignancies. Trials run by 0 other 0 organizations including individuals, universities and organizations displayed the most growth comprising 13-27% of studies in 2006 compared to 43-57% of trials in 2015. Percentage distribution by funder type for each malignancy is reflected in Figure 2 .
CONCLUSIONS: The funding of new trials for prostate, kidney and bladder cancer have each exhibited a progressive, sustained decrease in federally-funded trials across the last decade, while there has been in an increase in industry funded trials. It is critical to consider the sources of funding for clinical trials, and strive for balanced distribution of research funds. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1013
